CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 85 enrolled
Drug / intervention
Candesartandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04138316
NCT04138316N/ACompleted

CandeSpartan Study Candesartan Spanish Response-prediction and Tolerability Study Observational Study on Response Predictors and Tolerability of Candesartan in Usual Clinical Practice

Hospital Clínico Universitario de Valladolid·observational·Posted Oct 24, 2019·Updated Dec 19, 2022

In Brief

An observational study evaluating Candesartan for Migraine and Head Pain. Completed, enrolled 85 participants across 1 site.

Detailed Summary

Observational, prospective, descriptive, open study on response predictors and tolerability of Candesartan in patients \>18 years with episodic or chronic migraine with prior failure of three or more preventive drugs. Patients will receive Candesartan the same manner and intensity if they were not enrolled in the study. Vital signs, clinical variables and adverse events will be monitored. Primary endpoint will be to determine demographic and clinical factors associated with a 50% reduction in the frequency of headache days per month between weeks 20 and 24 compared with baseline.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, Head Pain
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedOct 24, 2019
Enrollment StartJan 2, 2020
Primary CompletionDec 16, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 6.7 years ago

Interventions

Candesartandrug

Treatment with Candesartan